Key Points
Demand for Abbott's medical devices and diagnostic tests is rising.
The company has increased its dividend for 54 straight years.
- 10 stocks we like better than Abbott Laboratories ›
Shares of Abbott Laboratories (NYSE: ABT) popped on Thursday after the healthcare products provider raised its full-year profit forecast.
Image source: Getty Images.
Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now, when you join Stock Advisor. See the stocks »
An intelligent acquisition is fueling Abbott's growth
Abbott's sales rose 13% to $12.6 billion in the second quarter, boosted by its $21 billion acquisition of cancer screening leader Exact Sciences in March.
The acquisition added more preventive products to Abbott's offerings, including Exact's market-leading noninvasive colorectal cancer screening test, Cologuard.
Abbott's worldwide diagnostics sales surged 42.3% to $3.1 billion.
Revenue in the healthcare giant's worldwide medical devices division also grew by a solid 9% to $5.9 billion, driven by an 11% jump in sales of continuous glucose monitors.
All told, Abbott's adjusted earnings rose 4% to $1.31 per share. That bested Wall Street's expectations, which had called for per-share profits of $1.28.
Higher profits mean larger dividends for investors
Looking ahead, Abbott sees its full-year comparable sales growing by 6.5% to 7.5% in 2026. Management also lifted its adjusted earnings per share outlook to between $5.45 and $5.60, up from a prior forecast of $5.38 to $5.58.
Abbott's strengthening profitability enables it to reward its shareholders with steadily rising cash payments. The medical devices and testing leader has raised its dividend for a remarkable 54 straight years.
Should you buy stock in Abbott Laboratories right now?
Before you buy stock in Abbott Laboratories, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Abbott Laboratories wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $397,351!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,304,257!*
Now, it’s worth noting Stock Advisor’s total average return is 934% — a market-crushing outperformance compared to 210% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
*Stock Advisor returns as of July 16, 2026.
Joe Tenebruso has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Abbott Laboratories. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
